{"id":"NCT01467427","sponsor":"Novo Nordisk A/S","briefTitle":"Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.","officialTitle":"Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-16","primaryCompletion":"2023-11-17","completion":"2023-11-17","firstPosted":"2011-11-08","resultsPosted":"2017-11-17","lastUpdate":"2025-01-28"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Bleeding Disorder","Haemophilia B"],"interventions":[{"type":"DRUG","name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]}],"arms":[{"label":"NNC-0156-000-0009","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Asia, Europe and North America. The aim of the trial is to evaluate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of NNC-0156-0000-0009 (nonacog beta pegol, N9-GP) in previously treated children with Haemophilia B.","primaryOutcome":{"measure":"Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU)","timeFrame":"From week 0 to week 52","effectByArm":[{"arm":"Younger Children (0-6 Years)","deltaMin":0,"sd":null},{"arm":"Older Children (7-12 Years)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"0 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":26,"countries":["United States","Brazil","Canada","Croatia","France","Germany","Italy","Japan","Malaysia","Taiwan","United Kingdom"]},"refs":{"pmids":["27174727","32369845"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":12},"commonTop":["Cough","Pyrexia","Contusion","Ligament sprain","Nasopharyngitis"]}}